SD
Therapeutic Areas
Teva Pharmaceutical Industries Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PONLIMSI™ (denosumab-adet) | Biosimilar to Xgeva®/Prolia® (osteoporosis, bone metastases) | Approved |
| Biosimilar to Xolair® (omalizumab) | Asthma, Chronic Spontaneous Urticaria | Under Regulatory Review |
| Biosimilar to Simponi® (golimumab) | Rheumatoid Arthritis, Psoriatic Arthritis | Clinical |
| Novel Immunology Candidate | Ulcerative Colitis, Crohn's Disease | Phase 3 |
| Novel Neuroscience Candidate | Multiple System Atrophy (MSA) | Phase 2 |
| Novel Immuno-Oncology Candidate | Attenukine Oncology | Phase 1 |
Leadership Team at Teva Pharmaceutical Industries
RF
Richard Francis
President and Chief Executive Officer
EL
Eli Lavie
Executive Vice President, Chief Financial Officer
DE
Dr. Eric Hughes
Executive Vice President, Global R&D and Chief Medical Officer
EL
Evan Lippman
Executive Vice President, Business Development